About allergy therapeutics plc - AGYTF
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company was founded by Keith Iain Carter in 1998 and is headquartered in Worthing, the United Kingdom.
AGYTF At a Glance
Allergy Therapeutics Plc
Dominion Way
Worthing, West Sussex BN14 8SA
| Phone | 44-1903-844-700 | Revenue | 71.21M | |
| Industry | Pharmaceuticals: Other | Net Income | -51,918,647.36 | |
| Sector | Health Technology | 2025 Sales Growth | 2.474% | |
| Fiscal Year-end | 06 / 2026 | Employees | N/A | |
| View SEC Filings |
AGYTF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.292 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -17.822 |
| Enterprise Value to Sales | 8.202 |
| Total Debt to Enterprise Value | 0.141 |
AGYTF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 6.518 |
| Total Asset Turnover | 0.816 |
AGYTF Liquidity
| Current Ratio | 1.275 |
| Quick Ratio | 0.764 |
| Cash Ratio | 0.47 |
AGYTF Profitability
| Gross Margin | 45.654 |
| Operating Margin | -53.603 |
| Pretax Margin | -73.476 |
| Net Margin | -72.909 |
| Return on Assets | -59.504 |
| Return on Equity | N/A |
| Return on Total Capital | -118.783 |
| Return on Invested Capital | -126.142 |
AGYTF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 188.39 |
| Total Debt to Total Assets | 88.964 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 182.496 |